Eli Lilly (LLY) Expands AdvanCell Partnership for Cutting-Edge Cancer Therapies
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
Eli Lilly Taps High-Grade Market to Fund Cancer Drug Purchase
Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...
Eli Lilly price target raised to $1,000 from $997 at BofA
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...
Hosted on MSN3d
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly Stock Rises After Earnings Beat Forecasts
Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...